[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trigger-finger-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trigger-finger-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100610443","phase-2-nac-repair-for-post-surgical-pain-100610443",false,"NCT07227649","NAC-REPAIR for Post-surgical Pain","NAC-REPAIR: N-Acetylcysteine-facilitated Redox-Immune Modulation for Post-surgical Analgesia and Injury Recovery","Inclusion Criteria:\n\n* Elective outpatient hand\u002Fupper-extremity or foot\u002Fankle surgery (single site; same-day discharge)\n* Baseline visit feasible ≤14 days pre-op\n* Can complete surveys\u002Fblood draw\n* Provides informed consent\n* Willing to follow dosing schedule and avoid restricted supplements\u002Fmeds\n\nExclusion Criteria:\n\n* Allergy to NAC\u002Fcapsule components □ NAC or high-dose antioxidants in past 14 days (unwilling to stop)\n* Chronic daily opioids ≥3 months or OUD\u002Fmaintenance therapy □ Pregnant\u002Fbreastfeeding or no contraception as applicable\n* Daily nitrates (nitroglycerin\u002Fisosorbide) □ Planned \\>24h admission, multistage\u002Ftrauma case □ Other interventional study within 30 days\n* Unable to swallow capsules \u002F malabsorption surgery affecting oral meds","ALL","18 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This pilot asks whether peri-operative N-acetylcysteine (NAC) improves recovery after common outpatient hand\u002Ffoot-ankle surgery-specifically, does NAC reduce pain and opioid use and enhance function by modulating redox-inflammatory pathways? Primary objectives are to establish feasibility (accrual, adherence, follow-up), estimate NAC vs placebo effects on pain, function, and opioid consumption, and characterize inflammatory signatures that may predict response.\n\nMethods: a single-site, double-blind, 1:1 randomized trial (N≈80) comparing NAC 1,200 mg twice daily for 14 days (starting pre-op) vs matching placebo; daily e-diaries for POD0-14; standardized outcomes (PROMIS Pain Interference; QuickDASH or FAAM; PGIC; opioid MME); and small blood draws pre-surgery and at two follow-up visits for cytokine profiling.",[27,28,29,30,31,32,33,34,35],"Carpal Tunnel Surgery","Trigger Finger Disorder","De Quervain Syndrome","Guyon's Canal","Dupuytren Contracture","Morton Neuroma","Tarsal Tunnel Syndrome","Plantar Fasciopathy","Peroneal Nerve Entrapment","NOT_YET_RECRUITING","2025-11-12",{"date":39,"type":40},"2025-11-14","ACTUAL",{"date":42,"type":21},"2026-01-15",{"date":44,"type":21},"2027-07-15",{"name":46,"class":47},"University of Arizona","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100552737","intrasynovial-digital-anesthesia-in-trigger-finger-100552737","NCT06476977","Intrasynovial Digital Anesthesia in Trigger Finger","Trigger Finger Corticosteroid Injection Pain: Palmar Injection Versus Dorsal Intrasynovial (Transthecal) Injection","Inclusion Criteria:\n\n* Be 18 years of age or older\n* Have a diagnosis of trigger finger (can be any of the 5 digits)\n* Opting to receive a CSI for their triggering finger\n\nExclusion Criteria:\n\n* Decline to obtain a CSI for trigger finger management\n* Receiving multiple CSI for trigger finger management at the appointment\n* Past CSI and\u002For surgery to the digit involved\n* Unable to communicate in English",{"count":57,"type":21},60,[59],"NA","Trigger finger is a common disease of the hand involving swelling and inflammation of the tendon which flexes a finger, causing catching, locking, and\u002For pain. Trigger finger is typically treated by hand surgeons with a steroid injection through the front\u002Fpalm side of the hand into the area near the tendon (i.e., at the base of the affected finger). This steroid injection is often combined with a local anesthetic (numbing agent) to help reduce short-term pain from the injection. However, the front\u002Fpalm side of the hand is known to be very sensitive, and the steroid injection can be quite painful as the needle pierces the front\u002Fpalm skin.\n\nTo reduce the pain of steroid injections for trigger finger, a different approach involves performing the injection from the back\u002Fdorsal side of the hand, which is thought to be less sensitive (and therefore less painful) than the front\u002Fpalm side of the hand. This technique is sometimes used and has been previously studied, but it is not clear if it can offer less injection-related pain than standard treatment.\n\nAccordingly, this study will be comparing short-term injection-associated pain between front\u002Fpalm side and back\u002Fdorsal side steroid injections for trigger finger. The study will also seek to understand what area of the hand is numbed by the anesthetic when doing a front\u002Fpalm side injection versus a back\u002Fdorsal side injection of the hand. Overall, the investigators hypothesize that back\u002Fdorsal side injections will be less painful than front\u002Fpalm side injections for trigger fingers and that the area of numbing from the anesthetic will be equivalent between both types of injections.",[28],[63,64,65,66,67,68],"trigger finger","stenosing tenosynovitis","corticosteroid injection","palmar","dorsal","pain","RECRUITING","2024-08-15",{"date":72,"type":40},"2024-08-19",{"date":74,"type":40},"2024-07-03",{"date":76,"type":21},"2026-07",{"name":78,"class":47},"Kevin Zuo",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100556992","phase-3-comparative-study-between-platelet-rich-plasma-and-steroid-injection-in-trigger-finger-treatment-100556992","NCT06532318","Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment","Comparative Study Between Intralesional Injection of Platelet Rich Plasma and Intralesional Steroid for the Treatment of Trigger Finger in Black Patients","Inclusion Criteria:\n\n* Patients who are 18year and above with mild or moderate trigger finger, who are willing to have intra-lesional administration of blood product.\n\nNo previous treatment for the affected finger.\n\nExclusion Criteria:\n\n* Previous steroid injection\n* Previous Surgery to that finger\n* Thrombocytopenic patients\n* Hand and finger contracture\n* Rheumatoid arthritis of the finger",{"count":87,"type":21},40,[89],"PHASE3","The goal of this clinical trial is to learn if platelet rich plasma works to treat early stage trigger finger in adults. It will also learn about the safety platelet rich plasma. The main questions it aims to answer are:\n\nDoes platelet rich plasma lower the pain associated with trigger finger of participants? Does it improve the hand grip strength and Q DASH score of participants? Researchers will compare platelet rich plasma to Depo-Medrol steroid (a known standard of care for early stage trigger finger) to see if platelet rich plasma works to treat early trigger finger.\n\nParticipants will:\n\nTake platelet rich plasma or a depo-medrol steroid intralesional injection at recruitment into the intervention Visit the clinic once every 4 weeks for checkups and parameter measurements. Investigator will will keep a record of participants progress in symptom remission",[28],"2024-07-31",{"date":94,"type":40},"2024-08-01",{"date":96,"type":21},"2024-07-24",{"date":98,"type":21},"2025-06-23",{"name":100,"class":47},"Obafemi Awolowo University Teaching Hospital"]